Bibliography
- Bulbulia R, Armitage J. LDL cholesterol targets - how low to go? Curr Opin Lipidol 2012;23:265-70
- Cholesterol Treatment Trialists' (CTT) Collaborators. Mihaylova B, Emberson J, Blackwell L, The effect of lowering LDL cholesterol with statin therapy in people at low risk of vacular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90
- Sniderman A, Thanassoulis G, Couture P, Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol 2012;6:303-9
- Mancini GBJ, Baker S, Bergeron J, Diagnosis, prevention and management of statin adverse events and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011;27:635-62
- Bruckert E, Hayem G, Delager S, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drug Ther 2005;19:403-14
- García-Rodríguez LA, Masso-Gonzalez EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008;17:943-52
- Giorgi M, Caroli C, Cohen Arazi H, Di Girolamo G. Pharmacogenomics and adverse drug reactions: the case of statins. Expert Opin Pharmacother 2011;12:1499-509
- Bhardwaj SS, Chalasani N. Lipid-lowering agents that causes drug-induced hepatotoxicity. Clin Liver Dis 2007;11:597-613
- Bader T. Yes! Statins can be given to liver patients. J Hepatol 2012;56:305-7
- Colbert JD, Stone JA. Statin use and the risk of incident diabetes mellitus: a review of the literature. Can J Cardiol 2012. [Epub ahead of print]
- Wong V, Stavar L, Szeto L, Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006;184:348-55
- Takagi T, Matsuda M, Abe M, Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008;196:114-21
- Keech A, Colquhoun D, Best J, Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003;26:2713-21
- Freeman D, Norrie J, Sattar N, Pravastatin and the development of diabetes: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001;103:357-62
- Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010;8:612-31
- Moutzouri E, Liberopoulos E, Mikhailidis DP, Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 2011;65(11):1141-8
- Rojas-Fernandez CH, Cameron J-CF. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012;46:549-57
- Fernandez AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008;134:824-30
- Corsini A, Bellosta S. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 2012:933-46
- Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf 2012;11:439-44